SiliconBeat

Insite Vision, the Alameda maker of ophthalmology products, was told last week that the company’s appeal of its proposed delisting by the NYSE Amex stock exchange was denied. Beginning Monday, April 20, Insite’s shares will begin trading on the Over-the-Counter Bulletin Board and Pink Sheets listings.

Insite was no longer in compliance with listing requirements because of insufficient shareholder equity and too many operating losses in recent years, according to a regulatory filing Tuesday.